Found 161 articles for: "ustekinumab"
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis
November 2018 | Volume 17 | Issue 11 | Original Article | 1211 | Copyright © November 2018
OBJECTIVE: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/t...
Read MoreOpen-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
October 2018 | Volume 17 | Issue 10 | Original Article | 1078 | Copyright © October 2018
INTRODUCTION: Response to etanercept therapy in patients who have failed apremilast therapy has not been well characterized. METHODS: In this multicenter, open-label, single-arm, phase 4, estimatio...
Read MoreWhat Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab
August 2018 | Volume 17 | Issue 8 | Supplement Individual Articles | 29 | Copyright © August 2018
Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe plaque psoriasis. However, based on safety signals identified in clinical ...
Read MoreDepression? It's the Disease NOT the Drug
August 2018 | Volume 17 | Issue 8 | Supplement Individual Articles | 28 | Copyright © August 2018
Research into the immunopathological mechanisms of plaque psoriasis has produced increasingly targeted biologic therapies. The specificity of these agents allows for high rates of efficacy and decreas...
Read MoreTreat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy
August 2018 | Volume 17 | Issue 8 | Editorials | 918 | Copyright © August 2018
Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial
August 2018 | Volume 17 | Issue 8 | Original Article | 873 | Copyright © August 2018
Background: Toreforant is a selective histamine H4 receptor antagonist. H4 receptor activation may play a role in immune-mediated inflammation in psoriasis. Objective: To evaluate Toreforant effica...
Read MoreA Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy
August 2018 | Volume 17 | Issue 8 | Original Article | 845 | Copyright © August 2018
Objective: To assess the effectiveness and safety of combining calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam with biologic therapies for patients with plaque psoriasis who have ...
Read MoreLong-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
August 2018 | Volume 17 | Issue 8 | Original Article | 826 | Copyright © August 2018
Background: Due to the chronic nature of psoriasis, it is important to assess the sustained response of treatments over time. Objective: To assess the efficacy of continuous treatment with guselkumab...
Read MoreThe Importance of Early Treatment in Psoriasis and Management of Disease Progression
July 2018 | Volume 17 | Issue 7 | Original Article | 737 | Copyright © July 2018
Psoriasis is a chronic, immune-mediated, inflammatory disease that if left untreated can result in prolonged subclinical inflammation that affects a variety of organs, including the heart, liver, kid...
Read MoreThe Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
May 2018 | Volume 17 | Issue 5 | Original Article | 539 | Copyright © May 2018
Interleukin 17 (IL-17) functions as a bridge between the innate and adaptive immunity. In addition to being a crucial defense mechanism against extracellular pathogens, it plays a significant role in ...
Read MoreOnset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis
March 2018 | Volume 17 | Issue 3 | Original Article | 247 | Copyright © March 2018
BACKGROUND: The advent of biologics has improved patient outcomes in the treatment of moderate-to-severe psoriasis. The time it takes for patients to see clinically meaningful improvement is an import...
Read MoreSafety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials
February 2018 | Volume 17 | Issue 2 | Original Article | 200 | Copyright © February 2018
BACKGROUND: Injection-site reactions (ISRs) are reported with biologic therapies. The objective of this study was to comprehensively characterize ISRs among moderate-to-severe psoriasis patients tr...
Read MorePrevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis
February 2018 | Volume 17 | Issue 2 | Original Article | 187 | Copyright © February 2018
IMPORTANCE: While psoriasis (Ps) is mainly characterized as an adult disease, it can also ...
Read MoreCost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis
December 2017 | Volume 16 | Issue 12 | Original Article | 1246 | Copyright © December 2017
BACKGROUND: Newer psoriasis treatments can achieve greater levels of effcacy than older systemic therapies; however, current pso-riasis costs are substantial. We sought to estimate costs per additi...
Read MoreReal-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis
December 2017 | Volume 16 | Issue 12 | Original Article | 1240 | Copyright © December 2017
OBJECTIVE: To examine real-world use and patient outcomes with apremilast, an oral PDE4 inhibitor, in the dermatology practice set-ting for treatment of patients with moderate to severe plaque psor...
Read MoreCombining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature
December 2017 | Volume 16 | Issue 12 | Original Article | 1209 | Copyright © December 2017
Psoriasis is a chronic inflammatory skin disease that affects millions of people in the United States as well as worldwide. While there is currently no cure for psoriasis, many treatment options ar...
Read MoreEvaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 1002 | Copyright © October 2017
BACKGROUND: Psoriasis is associated with increased risk of major adverse cardiovascular events (MACE). OBJECTIVES: Compare MACE risk with biologics vs topical/phototherapy use. METHODS: Psoriasis Lo...
Read MoreCost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 964 | Copyright © October 2017
INTRODUCTION: Biologic therapies have revolutionized the treatment of psoriasis; however, their use is limited by costs. Ixekizumab was more effective than etanercept in the UNCOVER trials, and the Fo...
Read MoreApremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 957 | Copyright © October 2017
BACKGROUND: Combining narrowband UVB (NB-UVB) phototherapy with biologics has been shown to enhance the therapeutic response of plaque psoriasis patients. The objective of this study was to evaluate t...
Read MoreSecukinumab: A Review of Safety and Efficacy in Psoriatic Arthritis
August 2017 | Volume 16 | Issue 8 | Supplement Individual Articles | 118 | Copyright © August 2017